Table 2. Multivariate model evaluating the association between SPARC, SPARC7 and relapse free survival in all patients and according to breast cancer subtype.

	Factors	HR [95% CI]	P-value
All patients	SPARCSPARC7*Tumor size (>2 cm vs. ≤2 cm)Nodal Status (positive vs. negative)Grade (III vs. II vs. I)Age (>50 vs.≤50)ER (positive vs. negative)HER2 (positive vs. negative)SPARC*ER (interaction)SPARC*HER2 (interaction)	1.2 [0.94–1.5]1.2 [0.99–1.6]1.3 [1.0–1.8]2.0 [1.2–3.2]1.4 [1.1–1.7]0.8 [0.6–1.1]0.9 [0.7–1.3]1.2 [0.8–1.8]0.5 [0.3–0.9]2.3 [0.9–6.2]	1.29E-015.32E-023.23E-023.69E-036.64E-041.86E-016.92E-013.14E-011.71E-029.33E-02
Basal	SPARCSPARC7 *Tumor size (>2 cm vs. ≤2 cm)Nodal Status (positive vs. negative)Grade (III vs. II vs. I)Age (>50 vs.≤50)	2.0 [1.1–3.7]2.2 [1.1–4.3]1.7 [0.8–3.9]0.5 [0.1–5.1]1.0 [0.48–2.1]0.6 [0.3–1.4]	2.28E-021.23E-021.77E-016.34E-019.98E-012.82E-01
HER2	SPARCSPARC7 *Tumor size (>2 cm vs. ≤2 cm)Nodal Status (positive vs. negative)Grade (III vs. II vs. I)Age (>50 vs.≤50)	2.3 [0.9–5.9]2.6 [1.1–6.7]1.6 [0.7–3.8]2.2 [0.8–6.3]0.9 [0.4–1.7]0.7 [0.8–0.3]	6.17E-023.80E-022.20E-011.30E-017.15E-017.36E-01
Luminal-A	SPARCSPARC7 *Tumor size (>2 cm vs. ≤2 cm)Nodal Status (positive vs. negative)Grade (III vs. II vs. I)Age (>50 vs.≤50)	0.8 [0.4–1.5]0.8 [0.4–1.6]1.8 [1.0–3.2]1.2 [0.4–3.7]1.3 [0.9–2.0]1.3 [0.8–2.3]	5.67E-016.14E-014.24E-027.20E-011.44E-012.81E-01
Luminal-B	SPARCSPARC7 *Tumor size (>2 cm vs. ≤2 cm)Nodal Status (positive vs. negative)Grade (III vs. II vs. I)Age (>50 vs.≤50)	1.2 [0.8–1.7]1.3 [0.9–1.8]1.1 [0.7–1.6]2.1 [1.0–4.4]1.3 [1.0–1.8]0.7 [0.8–0.3]	3.67E-011.56E-016.16E-013.48E-012.87E-021.28E-01

^*on inserting SPARC7 instead of SPARC in the model.